Project Title: Immune profiling of melanoma patients undergoing immunotherapies
PhD Awarded: October 2019
Since my childhood I have always been fascinated by the human body. When I started my Bachelor in Biology at the University of Lausanne (Switzerland) I had the opportunity to deepen my knowledge in a wide variety of subjects. For my Masters I decided to focus on Medical biology, namely Cancer and Immunology. I find this field extremely interesting and motivating, as the end goal of the studies is to help to improve thousands of patient’s lives.
Following my MSc, I had the opportunity to work for 7 months in a large and reputable pharmaceutical research organization (Nestlé Research Center) as a Junior Research Assistant. Then, I moved to the UK where I undertook a MRes in Biomedical Research at the University of Reading and carried out an 8 months research project on the regulation of metastasis in Rhabdomyosarcoma. I am currently pursuing a PhD aimed at profiling immune responses in melanoma patients undergoing immunotherapy at the University of Zürich Hospital (Switzerland). This position will also help improve my level of German as I was born in the west part of Switzerland and my first language is French.
Regarding my extracurricular activities, I enjoy travelling and doing all kinds of sports, which I like to teach as well. I have done a season as a ski/snowboard instructor and taught tennis for many years. I enjoy coaching, I find it very rewarding.
Ramelyte E, Schindler SA, Dummer R. The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opin Drug Saf. 2017 Jan;16(1):41-53.
Dummer R, Ramelyte E, Schindler S, Thurigen O, Levesque MP, Koelblinger P. MEK inhibition and immune responses in advanced melanoma. Oncoimmunology. 2017 Aug 10;6(8):e1335843. Available at: https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1335843
Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson MD, Levesque MP, Becher B. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018; 24(2):144-153. Available at: https://www.nature.com/articles/nm.4466. Erratum in: Nat Med. 2018; 24(11):1773-1775.
Hogan SA, Levesque MP, Cheng PF. Melanoma Immunotherapy: Next-Generation Biomarkers. Front Oncol. 2018 May 29;8:178. Available at: https://www.frontiersin.org/articles/10.3389/fonc.2018.00178/full
Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, Perez S, Plantier N, Mouret JF, Nguyen-Kim TDL, Raaijmakers MIG, Kvistborg P, Pasqual N, Haanen JBAG, Dummer R, Levesque MP. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res. 2019; 7(1):77-85. Available at: https://cancerimmunolres.aacrjournals.org/content/7/1/77
Poźniak J, Nsengimana J, Laye JP, O’Shea SJ, Diaz JMS, Droop AP, Filia A, Harland M, Davies JR, Mell T, Randerson-Moor JA, Muralidhar S, Hogan SA, Freiberger SN, Levesque MP, Cook GP, Bishop DT, Newton-Bishop J. Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Res. 2019 May 15;79(10):2684-2696. Available at: https://cancerres.aacrjournals.org/content/79/10/2684